Patents by Inventor Richard L. Eckert

Richard L. Eckert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating resistant cancers
    Patent number: 11246856
    Abstract: Provided herein is a method for reducing resistance in an individual having a drug resistant cancer, for example, a BRAF inhibitor resistant cancer. A Hippo signaling pathway inhibitor such as a Yes-associated protein 1 (YAP1) inhibitor, a Transcriptional Coactivator with PDZ-binding motif (TAZ) inhibitor, a Transcription enhancer domain (TEAD) inhibitor or a combination of these is administered. Also provided is a method of treating BRAF inhibitor resistance in an individual with a BRAF inhibitor resistant cancer, for example, malignant melanoma, with a Hippo signaling pathway inhibitor, such as Verteporfin, and a BRAF inhibitor.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: February 15, 2022
    Assignee: University of Maryland, Baltimore
    Inventors: Richard L. Eckert, Matthew Fisher, Daniel Grun, Gautam Adhikary, Wen Xu
  • TG2 inhibitor piperazine compounds and uses thereof
    Patent number: 10894777
    Abstract: There are provided Tissue Transglutaminase (TG2) inhibitor compounds, and compositions and methods of use thereof for the prevention or treatment of a cancer.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: January 19, 2021
    Assignees: UNIVERSITY OF OTTAWA, UNIVERSITY OF MARYLAND, BALTIMORE, UNIVERSITY OF ROCHESTER
    Inventors: Jeffrey W. Keillor, Abdullah Akbar, Richard L. Eckert, Matthew Fisher, Gail V. W. Johnson
  • Methods of Treating Resistant Cancers
    Publication number: 20200147047
    Abstract: Provided herein is a method for reducing resistance in an individual having a drug resistant cancer, for example, a BRAF inhibitor resistant cancer. A Hippo signaling pathway inhibitor such as a Yes-associated protein 1 (YAP1) inhibitor, a Transcriptional Coactivator with PDZ-binding motif (TAZ) inhibitor, a Transcription enhancer domain (TEAD) inhibitor or a combination of these is administered. Also provided is a method of treating BRAF inhibitor resistance in an individual with a BRAF inhibitor resistant cancer, for example, malignant melanoma, with a Hippo signaling pathway inhibitor, such as Verteporfin, and a BRAF inhibitor.
    Type: Application
    Filed: May 18, 2018
    Publication date: May 14, 2020
    Applicant: University of Baltimore, Maryland
    Inventors: Richard L. Eckert, Matthew Fisher, Daniel Grun, Gautam Adhikary, Wen Xu
  • TG2 INHIBITOR COMPOUNDS AND USES THEREOF
    Publication number: 20190389814
    Abstract: There are provided Tissue Transglutaminase (TG2) inhibitor compounds, and compositions and methods of use thereof for the prevention or treatment of a cancer.
    Type: Application
    Filed: April 13, 2017
    Publication date: December 26, 2019
    Applicants: UNIVERSITY OF OTTAWA, UNIVERSITY OF MARYLAND, BALTIMORE, UNIVERSITY OF ROCHESTER
    Inventors: Jeffrey W. KEILLOR, Abdullah AKBAR, Richard L. ECKERT, Matthew FISHER, Gail V. W. JOHNSON
  • Tissue specific promoters and transgenic mouse for the screening of pharmaceuticals
    Patent number: 6313373
    Abstract: The present invention provides human involucrin (hINV) sequences having tissue specific and cell type specific promoter activity. The sequences provided herein direct expression to suprabasal cells of stratifying epithelia. The invention further provides methods for the production of transgenic animals which contain a hINV promoter sequence which directs the expression of human papillomavirus 16 oncogenes (or other oncogenes). These animals display cervical and epidermal hyperplasias as well as cancer of the trachea, esophagus, colon, epidermis, anus/rectum, lymph nodes, spleen and lung. The animals of the invention provide a useful model for screening potential anti-neoplastic compounds, carcinogens, and co-carcinogens for a number of cancers.
    Type: Grant
    Filed: October 29, 1999
    Date of Patent: November 6, 2001
    Assignee: Case Western Reserve University
    Inventors: Richard L. Eckert, James F. Crish
  • Bandage for continuous application of biologicals
    Patent number: 5487889
    Abstract: The present invention provides a biological bandage, comprising an envelope enclosing cells which secrete biologically active cellular products such as growth factors, which promote the healing of wounds. The envelope is further comprised of a permeable bottom membrane through which the cellular product diffuses, and a top membrane. Preferably the bandage has a separator interposed between the two membranes. This invention also relates to a method for treating wounds. The bandage provides a continuous, uniform source of fresh cellular product.
    Type: Grant
    Filed: August 13, 1993
    Date of Patent: January 30, 1996
    Assignees: The MetroHealth System, The University of Akron, Case Western Reserve University
    Inventors: Richard L. Eckert, Daniel J. Smith, Irwin Schafer